Merck halts enrollment on two PhIII Keytruda combo studies as outside monitors flag a worrying rate of deaths
Merck $MRK has had to hit the brakes on enrolling new patients for two of its late-stage combo studies involving its blockbuster checkpoint Keytruda after …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
